{"id":"preservative-free-tafluprost-or-vehicle","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eyelid skin darkening"},{"rate":"5-10%","effect":"Periorbital fat atrophy"},{"rate":"5-10%","effect":"Eyelash growth"},{"rate":"5%","effect":"Itching"},{"rate":"5%","effect":"Redness of the eye"},{"rate":"5%","effect":"Dry eye"},{"rate":"5%","effect":"Eye irritation"},{"rate":"5%","effect":"Headache"},{"rate":"5%","effect":"Dizziness"},{"rate":"5%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tafluprost works by mimicking the action of prostaglandin F2α, a naturally occurring substance in the body that helps to reduce intraocular pressure. This is achieved by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby reducing the pressure in the eye. This mechanism of action is similar to other prostaglandin analogues used to treat glaucoma.","oneSentence":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:10.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"}]},"trialDetails":[{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01306461","phase":"PHASE3","title":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-03","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":401}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-2452"],"phase":"phase_3","status":"active","brandName":"Preservative-Free Tafluprost or vehicle","genericName":"Preservative-Free Tafluprost or vehicle","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow. Used for Glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}